CBS62logoNEW2013_blue_final_header_White wwj950-sm2011b 971-ticket-35smb 35h_CBSSportsRad_Detroit

zinc

stents

Michigan Tech Studying Better Stents

Researchers at Michigan Technological University want to create a coronary artery stent that won’t produce long term side effects. They think they may have found the answer in zinc.

WWJ Newsradio 950–04/30/2013

adeona2

Adeona Reports Positive Study Results For Zinc Treatment Of ALS

Pharma startup Adeona and its research partner report no safety issues related to high doses of zinc to slow the effects of Lou Gehrig’s Disease

WWJ Newsradio 950–11/30/2011

adeona2

Adeona Loss Grows, But Drug Trials Continue

The pharma startup Adeona Pharmaceuticals Inc. (AMEX: AEN), a developer of innovative medicines for serious central nervous system diseases, reported its third quarter 2011 financial results Monday.

WWJ Newsradio 950–11/14/2011

HR Notices From August 25

The latest personnel and boardroom announcements from Michigan’s technology-focused companies and institutions

WWJ Newsradio 950–08/25/2011

adeona2

Adeona Loss Grows, But Milestones Reached

Ann Arbor-based Adeona Pharmaceuticals Inc. (AMEX: AEN), a developer of medicines for serious central nervous system diseases, Monday reported its second quarter financial results for the period ended June 30, as well as updates since the beginning of the second quarter.

WWJ Newsradio 950–08/15/2011

umlogo

Preventing Diabetes Damage: Zinc’s Effects On A Kinky, Two-Faced Cohort

In type 2 diabetes, a protein called amylin forms dense clumps that shut down insulin-producing cells, wreaking havoc on the control of blood sugar. But zinc has a knack for preventing amylin from misbehaving. Recent research at the University of Michigan offers new details about how zinc performs this “security guard” function.

WWJ Newsradio 950–06/30/2011

adeona

Adeona Announces Positive Alzheimer’s Subgroup Analysis

Ann Arbor-based Adeona Pharmaceuticals Inc. (NYSE Amex: AEN) Thursday announced positive findings based on further analyses from the clinical study evaluating its product reaZin along with near-term plans for its Alzheimer’s disease program.

WWJ Newsradio 950–06/02/2011

adeona

Adeona’s Alzheimer’s Study Accepted For Neurology Meeting

Ann Arbor-based Adeona Pharmaceuticals Inc. said Tuesday that an abstract on its pivotal clinical trial of its zinc and cysteine-based product candidate being evaluated in patients with Alzheimer’s disease and mild cognitive impairment has been accepted for presentation at the 2011 American Academy of Neurology Annual Meeting in April.

02/08/2011

Event Notices From January 18

The latest event and meeting notices from Michigan’s technology community, before they’re posted on the GLITR IT Calendar

01/18/2011

UM Study: 'Security Guard' Zinc Off Duty In Diabetes

In type 2 diabetes, a protein called amylin forms dense clumps that shut down insulin-producing cells, wreaking havoc on the control of blood sugar. But in people without diabetes, amylin doesn’t misbehave; it actually pitches […]

07/18/2010